Progress in bipolar androgen therapy for castration resistant prostate cancer
- VernacularTitle:双极雄激素疗法治疗去势抵抗性前列腺癌的研究进展
- Author:
Meikai ZHU
1
;
Jian WANG
;
Sifeng QU
;
Qiujie ZHANG
;
Shouzhen CHEN
;
Wenfu WANG
;
Shuo WANG
;
Hu GUO
;
Benkang SHI
;
Yaofeng ZHU
Author Information
- Keywords: Prostatic neoplasms; Carcinoma; Bipolar androgen therapy; Castration-resistant prostate cancer; Drug synergy; Androgen receptor
- From: Chinese Journal of Urology 2023;44(12):953-956
- CountryChina
- Language:Chinese
- Abstract: Bipolar androgen therapy (BAT), as a new therapy, can effectively reduce the serum prostate specific antigen (PSA) level of a part of patients with castration resistant prostate cancer (CRPC), delay tumor progression, improve their quality of life and restore the sensitivity to drug therapy. This paper will review the background, possible mechanism, clinical research progress and development prospect of BAT.
